证券代码：600530 证券简称：*ST 交昂 公告编号：临 2023-078 上海交大昂立股份有限公司 关于公司股票交易风险提示公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 公司聘任 2022 年度年报审计机构事项尚需经公司 2023 年第四次临时股东大会 审议通过，该会议定于 8 月 23 日召开。根据《股票上市规则》相关规定，上市公司聘 请或者解聘会计师事务所必须由股东大会决定，董事会不得在股东大会决定前委托会计 师事务所开展工作。如公司未在 9 月 4 日内披露经审计的 2022 年年度报告，公司股票 将被终止上市。 ● 公司本次年报审计情况复杂，审计窗口期时间较短，且涉及前期多项会计差错更 正事项，仍存在可能无法按时披露经审计的 2022 年年度报告的风险。 ● 若公司 2022 年度财务会计报告被出具无法表示意见或否定意见的审计报告，公 司股票将继续被实施退市风险警示。 一、二级市场交易风险提示 截至2023年8月10日，公司股票收盘价为2.21元/股。公司股票于2023年8月9日触 及 ...

证券代码：600530 证券简称：*ST 交昂 公告编号：2023-076 上海交大昂立股份有限公司 关于 2023 年第四次临时股东大会增加临时提案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 股东大会有关情况 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | Ａ股 | 600530 | *ST 交昂 | 2023/8/15 | 二、 增加临时提案的情况说明 1. 提案人：上海韵简实业发展有限公司、上海饰杰装饰设计工程有限公司 2. 提案程序说明 公司已于 2023 年 8 月 8 日公告了股东大会召开通知，分别持有 10.63%、5.45%股份 的股东上海韵简实业发展有限公司、上海饰杰装饰设计工程有限公司在 2023 年 8 月 9 日提出临时提案并书面提交股东大会召集人。股东大会召集人按照《上市公司股东大会 规则》有关规定，现予以公告。 3. 临时提案的具体内容 上海韵简实业发展有限公司（以下简称："上海韵简"）、上海饰杰装饰设计工程有 ...

1.1 审议通过《关于增补张顺先生为公司第八届监事会监事候选人的议案》 同意增补张顺先生为公司第八届监事会监事候选人，并将此议案作为临时提案提交 公司 2023 年第四次临时股东大会审议。 赞成 3 票，反对 0 票，弃权 0 票，审议通过。 第八届监事会第十一次会议决议公告 本公司监事会及全体监事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海交大昂立股份有限公司（以下简称"公司"）第八届监事会第十一次会议于 2023 年 8 月 9 日以通讯表决的方式召开。会议通知和材料已于会前送达各位监事。会议 应参加表决监事 3 人，实际参加表决监事 3 人，本次会议召开程序符合《公司法》和《公 司章程》的有关规定，经监事审议表决，通过以下议案： 1、审议通过《关于增补第八届监事会监事候选人的议案》 1.2 审议通过《关于增补李家儒先生为公司第八届监事会监事候选人的议案》 同意增补李家儒先生为公司第八届监事会监事候选人，并将此议案作为临时提案提 交公司 2023 年第四次临时股东大会审议。 证券代码：600530 证券简称：*ST 交昂 公告编号：临 ...

关于《上海交大昂立股份有限公司 股票交易异常波动问询函》的回函 上海交大昂立股份有限公司: 本公司及其一致行动人于 2023年8月9日收到贵公司发来的《上海交大昂 立股份有限公司关于股票交易异常波动的间询函》,经本公司及其一致行动人认 真自查核实,现将有关问题回复如下: 一、截至目前,本公司不存在涉及上海交大昂立股份有限公司(以下简称"交 大昂立")应披露而未披露的重大信息。 二、截至目前,本公司不存在处于筹划阶段的涉及交大昂立的重大事项,包 括但不限于重大资产重组、股份发行、收购、债务重组、业务重组、资产剥离、 资产注入、股份回购、股权激励、破产重整、重大业务合作、引进战略投资者等 重大事项。 三、在本次股票交易异常波动期间,本公司不存在买卖交大昂立股票的情形。 特此回复。 上海饰杰装饰设计工程有 科技发展合伙企业(有限台 水农帮咨询合伙企业(有 关于《上海交大昂立股份有限公司 股票交易异常波动问询函》的回函 上海交大昂立股份有限公司: 二、截至目前,本人不存在处于筹划阶段的涉及交大昂立的重大事项,包括 但不限于重大资产重组、股份发行、收购、债务重组、业务重组、资产剥离、资 产注入、股份回购、股权激励、破产 ...

证券代码：600530 证券简称：*ST 交昂 公告编号：临 2023-077 ● 根据《股票上市规则》第9.4.13条第（二）项规定，若公司股票被实施退市风 险警示后2个月内仍未披露经审计的2022年年度报告和2023年第一季度报告，公司股票 将被终止上市。敬请广大投资者注意投资风险。 一、股票交易异常波动的具体情况 公司股票在8月7日、8月8日、8月9日连续三个交易日内收盘价格涨幅偏离值累计 超12%，根据《上海证券交易所交易规则（2023年修订）》的相关规定，属于股票交易 异常波动情形。 二、公司关注并核实的相关情况 上海交大昂立股份有限公司 关于公司股票交易异常波动的公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 上海交大昂立股份有限公司（以下简称"公司"）股票在8月7日、8月8日、8 月9日连续三个交易日内收盘价格涨幅偏离值累计超12%，根据《上海证券交易所交易 规则（2023年修订）》的相关规定，属于股票交易异常波动情形。 ● 经公司自查及书面发函询问控股股东、实际控制人，截止本公告披露日 ...

关于增补第八届监事会监事候选人的公告 本公司监事会及全体监事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600530 证券简称：*ST 交昂 公告编号：临 2023-075 上海交大昂立股份有限公司 上海交大昂立股份有限公司（以下简称"公司"）股东监事李一贺先生、朱莹政 先生已辞任第八届监事会股东监事。具体内容详见公司于 2023 年 1 月 21 日、4 月 28 日披露的《关于公司监事辞职及补选职工代表监事的公告》《关于公司监事辞职的公 告》（公告编号：临 2023-005、临 2023-021）。 经公司股东上海韵简实业发展有限公司及其一致行动人上海饰杰装饰设计工程有 限公司推荐，在征得本人同意后，公司第八届监事会第十一次会议审议通过了《关于增 补第八届监事会监事候选人的议案》（同意 3 票，反对 0 票，弃权 0 票），公司监事会同 意提名张顺先生、李家儒先生为公司第八届监事会监事候选人（简历见附件），任期自 公司股东大会审议通过之日起至本届监事会任期届满之日止，并将此议案作为临时提案 提交公司 2023 年第四次临时股东大会 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥161,912,619.04, a decrease of 9.24% compared to ¥178,398,351.17 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was ¥11,731,826.35, down 42.56% from ¥20,424,555.96 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,990,071.24, a decrease of 26.40% compared to ¥16,289,819.66 in the same period last year[21]. - Basic earnings per share decreased by 42.15% to CNY 0.015 compared to the previous period[23]. - Diluted earnings per share also decreased by 42.15% to CNY 0.015[23]. - The weighted average return on equity dropped by 0.98 percentage points to 1.33%[23]. - The company reported a total of CNY -258,244.89 in non-recurring losses after tax adjustments[25]. - The net profit for the first half of 2022 was CNY 13,439,891.33, a decline of 41.9% compared to CNY 23,128,202.61 in the first half of 2021[104]. - The company reported a total comprehensive income of CNY 8,882,355.32, down from CNY 24,344,292.52 year-on-year[105]. Cash Flow and Assets - The net cash flow from operating activities increased by 6.18% to ¥41,495,647.66 from ¥39,080,452.35 in the previous year[21]. - The total assets at the end of the reporting period were ¥1,403,191,152.75, an increase of 3.76% from ¥1,352,345,202.99 at the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were ¥883,024,939.34, up 0.82% from ¥875,850,649.00 at the end of the previous year[21]. - The total cash and cash equivalents at the end of the period were 167,094,608.20 RMB, up from 86,402,028.05 RMB at the end of the first half of 2021[111]. - The total liabilities increased to CNY 480,739,699.81, compared to CNY 438,776,105.37 at the beginning of the period, reflecting an increase of 9.6%[96]. - The company's equity attributable to shareholders rose to CNY 883,024,939.34, up from CNY 875,850,649.00, marking an increase of 0.1%[96]. Business Operations - The main business includes the R&D, production, and sales of food and health food products, as well as the operation and management of elderly medical care institutions[26]. - The health food segment's production includes self-produced and outsourced products, with various product lines such as oral liquids and capsules[27]. - The sales model combines offline and online channels, with offline sales through major retailers and pharmacies, and online sales through TV shopping and e-commerce[28]. - The health food industry is expected to grow due to increasing disposable income and a rising willingness to pay for health products[28]. - The company anticipates that the demand for functional health foods will create greater market opportunities in the future[28]. - The company's medical care segment generated a total operating income of RMB 81.1 million, with a net profit attributable to the parent company of RMB 22.9 million during the reporting period[39]. - The total number of beds occupied at the end of June was 2,805, reflecting a year-on-year decrease of approximately 3.5% due to pandemic-related restrictions[39]. Risk Management - The company has detailed potential risks in the management discussion and analysis section of the report[7]. - The company faces risks from strict industry regulations, raw material price fluctuations, and reliance on medical insurance payments[50]. Corporate Governance - The company held two shareholder meetings during the reporting period, complying with legal regulations and ensuring valid resolutions[55]. - The board of directors underwent significant changes, with new appointments including Ji Lin as Chairman and Zhang Yunjian as President[56]. - The company has not reported any significant changes in its corporate governance structure beyond the recent board elections[57]. Environmental Responsibility - The company faced an administrative fine of 360,000 RMB due to environmental compliance issues related to wastewater treatment[61]. - The company is committed to environmental responsibility, conducting regular maintenance on wastewater systems to prevent leaks[62]. - The company implemented energy-saving measures in its boilers, achieving an annual reduction of approximately 195 tons of standard coal through improved heat recovery[63]. Shareholder Information - As of the end of the reporting period, the total number of ordinary shareholders is 34,819[79]. - The largest shareholder, Dazhong Transportation Group Co., Ltd., holds 14.38% of the shares, totaling 112,184,187 shares[81]. - Shanghai Yunjian Industrial Development Co., Ltd. holds 10.56% of the shares, totaling 82,362,600 shares[82]. - The company approved a share repurchase plan with a total amount not less than RMB 25 million and not exceeding RMB 50 million, with a maximum repurchase price of RMB 6.91 per share[84]. Research and Development - R&D expenses increased due to higher investment in research and development[42]. - The company has obtained 34 national patent authorizations, including 9 for probiotic inventions, showcasing its strong technological capabilities[31]. Financial Management - The company has established a cost control analysis system to monitor operational costs across various levels, enhancing its competitive advantage in cost management[36]. - The company has achieved a significant reduction in financial expenses by 75.97%, from RMB 8.9 million to RMB 2.1 million[40]. - The company reported a decrease in investment income due to the disposal of Suzhou Sanxiang Road Elderly Apartment in the previous period[42]. Compliance and Reporting - The report has not been audited, and the management has confirmed the accuracy and completeness of the financial report[5]. - The financial statements are prepared based on the enterprise accounting standards, reflecting the company's financial status and operating results accurately[136].

Financial Performance - In 2021, the company's operating revenue was CNY 362,576,663.60, an increase of 8.98% compared to CNY 332,695,487.68 in 2020[21] - The net profit attributable to shareholders of the listed company for 2021 was CNY 37,177,627.01, a decrease of 59.88% from CNY 92,670,121.92 in 2020[21] - The net profit after deducting non-recurring gains and losses was CNY 25,330,968.24, representing a significant increase of 258.85% compared to CNY 7,058,882.62 in 2020[21] - The cash flow from operating activities for 2021 was CNY 104,062,540.92, up 54.90% from CNY 67,178,715.33 in 2020[21] - The total revenue for the year 2021 was 363 million RMB, representing a year-on-year increase of 8.98%[45] - The net profit attributable to shareholders was 37 million RMB, a significant decrease of 59.88% compared to the previous year, primarily due to the sale of a subsidiary[45] Assets and Liabilities - As of the end of 2021, the total assets amounted to CNY 1,352,345,202.99, an increase of 4.51% from CNY 1,293,961,078.31 at the end of 2020[21] - The net assets attributable to shareholders of the listed company were CNY 875,850,649.00, reflecting a 4.90% increase from CNY 834,900,061.69 in 2020[21] - Cash and cash equivalents increased by 38.49% to 163.43 million yuan, accounting for 12.08% of total assets[61] - Inventory rose by 29.57% to 55.67 million yuan, representing 4.12% of total assets[61] - Long-term equity investments decreased by 59.23% to 27.71 million yuan, accounting for 2.05% of total assets[61] - Short-term borrowings decreased by 37.50% to 50 million yuan, representing 3.70% of total liabilities[61] Profitability and Margins - Basic earnings per share for 2021 were CNY 0.05, down 57.98% from CNY 0.119 in 2020[22] - The weighted average return on equity decreased by 7.04 percentage points to 4.17% in 2021[23] - The company achieved a gross profit margin of 43.0% in its main business operations, indicating stable profitability[50] - The gross profit margin for the overall business was 42.83%, reflecting an increase of 2.29 percentage points from the previous year[51] - The gross profit margin for the health products segment was 58.67%, which increased by 13.23 percentage points[54] Business Segments and Growth - The company achieved a turnaround in the health product segment, marking its first profit in nearly seven years[29] - The raw material business saw significant growth, particularly in exports, due to enhanced R&D efforts and improved production management[29] - The healthcare segment reported a revenue of CNY 159,768,650.32, with a year-on-year growth of 37.49%[51] - The company operates six self-managed profit-oriented elderly medical care institutions, providing services such as medical care, rehabilitation, nursing, and health management[40] - The company’s health supplement products include probiotics and herbal extracts, targeting various health needs such as immune enhancement and blood lipid regulation[36] Research and Development - The company's R&D expenses increased by 22.65% to 15.64 million RMB, reflecting a commitment to technological innovation[47] - The company holds 18 Chinese invention patents, including 11 related to probiotics, showcasing its strong technological capabilities[42] - The company has completed the technical development of high-activity probiotic raw materials for dairy products, improving production efficiency and reducing costs by over 30%[70] - The company has made significant investments in research and development, focusing on products that align with market trends and consumer health needs[69] Market Trends and Opportunities - The health supplement industry in China reached a sales figure of 198.4 billion yuan in 2020, showing a year-on-year growth of 11.52%[33] - The projected market size of the health supplement industry is expected to reach approximately 517.8 billion yuan by 2026, maintaining a growth rate of at least 4% over the next five years[33] - The company aims to expand its probiotic product line and enhance its competitive edge through differentiated strategies[87] - The company is focusing on mid-range elderly medical care institutions and deepening its presence in the Yangtze River Delta region[87] Corporate Governance and Compliance - The company has received a standard unqualified audit opinion from Da Xin Accounting Firm[4] - The company maintains independence from its controlling shareholder in terms of assets, personnel, and financial management[101] - The company has established an independent financial accounting department with dedicated personnel and a standardized financial management system[102] - The company has established a performance evaluation system linking executive compensation to business performance[99] Social Responsibility and Environmental Initiatives - The company actively participates in social responsibility initiatives, including health education programs and community support[144] - The company has invested in upgrading wastewater treatment facilities to enhance environmental protection efforts[145] - The company implemented a central air conditioning cooling water system renovation project, expected to save approximately 150 tons of standard coal annually[142] Challenges and Risks - The company faced significant impacts on operations and business due to the COVID-19 pandemic, affecting the opening and occupancy rates of its facilities[151] - The company is exposed to risks from policy changes affecting healthcare payments and rising labor costs in the medical care sector[93] - The healthcare food industry faces increasing regulatory scrutiny, necessitating compliance with new laws and internal management standards[92]

Financial Performance - Q1 2022 revenue was CNY 91,400,747.06, a decrease of 1.57% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 9,167,962.88, down 43.76% year-on-year[3] - Basic earnings per share decreased by 42.86% to CNY 0.012[3] - Total operating revenue for Q1 2022 was CNY 91,400,747.06, a decrease of 1.6% from CNY 92,854,861.84 in Q1 2021[18] - Net profit for Q1 2022 was CNY 12,364,513.47, compared to CNY 18,876,329.99 in Q1 2021, indicating a decline of 34.4%[19] - Total comprehensive income for Q1 2022 was CNY 13,164,513.47, a decrease from CNY 19,814,419.90 in Q1 2021[20] - Basic and diluted earnings per share for Q1 2022 were CNY 0.012, down from CNY 0.021 in Q1 2021[20] Cash Flow and Liquidity - Net cash flow from operating activities was negative CNY 7,096,727.48, a decline of 362.98%[3] - The company's cash and cash equivalents decreased to CNY 308,851,349.44 in Q1 2022 from CNY 332,098,052.13 in Q1 2021, indicating liquidity challenges[18] - Cash received from sales of goods and services in Q1 2022 was CNY 85,158,920.06, an increase from CNY 80,738,031.10 in Q1 2021[22] - Cash paid for purchasing goods and services in Q1 2022 was CNY 31,837,059.98, up from CNY 23,802,468.08 in Q1 2021[23] - Net cash flow from investing activities for Q1 2022 was CNY -19,423,006.75, a decrease from CNY 5,267,523.83 in Q1 2021[23] - Total cash outflow from financing activities in Q1 2022 was CNY 8,620,187.28, compared to CNY 63,685,066.66 in Q1 2021[24] - The company reported a decrease in cash received from other operating activities, totaling CNY 5,210,181.56 in Q1 2022, down from CNY 11,824,472.93 in Q1 2021[23] - The company experienced a foreign exchange loss of CNY -33,641.02 in Q1 2022, compared to a gain of CNY 115,501.64 in Q1 2021[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,381,665,800.16, an increase of 2.17% from the end of the previous year[4] - The total liabilities for Q1 2022 were CNY 454,932,189.07, compared to CNY 438,776,105.37 in Q1 2021, showing an increase in financial obligations[17] - The equity attributable to shareholders increased to CNY 885,818,611.88 in Q1 2022 from CNY 875,850,649.00 in Q1 2021, reflecting a stable capital position[18] Shareholder Changes - A total of 124,590,064 shares, representing 15.97% of the total share capital, were transferred through agreements among major shareholders during the reporting period[12] - After the transfer, Shanghai Yunjian Industrial Development Co., Ltd. and its concerted actors held a total of 124,590,064 shares, which is 15.97% of the total share capital[13] - The major shareholder, Shanghai New South Ocean Anli Education Technology Co., Ltd., currently holds 66,446,889 shares, accounting for 8.52% of the total share capital[10] - The company has seen significant changes in its major shareholders, with the transfer of 39,072,641 shares (5.01% of total capital) to Lishui Nongbang Consulting Partnership[10] - The company’s major shareholders, including Zhongjin Investment Group Co., Ltd., have undergone significant share transfers, impacting their ownership structure[11] Research and Development - R&D expenses increased by 29.23% as the company intensified its investment in research and development[6] - The company's R&D expenses increased to CNY 4,223,086.94 in Q1 2022, up from CNY 3,267,947.35 in Q1 2021, highlighting a focus on innovation[18] Other Observations - The company reported a 100.10% decrease in asset disposal gains compared to the same period last year[6] - The company’s financial statements for the first quarter of 2022 are unaudited, indicating a need for caution in interpreting the financial data[14] - The company has not reported any significant new strategies or product developments during the quarter[14] - The company's trading financial assets remained stable at RMB 12,141,976.76 as of March 31, 2022, unchanged from the previous period[15] - Accounts receivable increased by 18.86% due to impacts from the pandemic[5] - The company reported accounts receivable of RMB 98,573,920.46 as of March 31, 2022, compared to RMB 83,059,404.14 as of December 31, 2021, indicating an increase of approximately 18.8%[15] - Cash and cash equivalents at the end of Q1 2022 were CNY 128,257,038.56, compared to CNY 62,408,602.84 at the end of Q1 2021[24] - The company reported an investment loss of CNY 20,566.74 in Q1 2022, compared to a gain of CNY 10,013.47 in Q1 2021, indicating challenges in investment performance[19] - The company’s short-term borrowings remained stable at CNY 50,000,000.00 in both Q1 2022 and Q1 2021, reflecting a consistent financing strategy[17]

Revenue and Profit - Revenue for Q3 2021 was CNY 83,091,191.37, a decrease of 12.96% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 3,329,275.88, down 86.08% year-on-year[4] - Net profit excluding non-recurring gains and losses increased by 33.54% to CNY 2,729,348.01[4] - Basic earnings per share decreased by 86.67% to CNY 0.004[5] - Total operating revenue for the first three quarters of 2021 reached ¥261,489,542.54, an increase from ¥251,919,577.93 in the same period of 2020, representing a growth of approximately 3.5%[19] - Net profit for the third quarter of 2021 was ¥27,449,953.98, down from ¥57,422,437.31 in the same quarter of 2020, reflecting a decline of approximately 52.2%[20] - The comprehensive income total for the third quarter of 2021 was ¥28,666,043.89, down from ¥59,877,397.08 in the same quarter of 2020, reflecting a decline of about 52.1%[21] - Basic earnings per share for the third quarter of 2021 were ¥0.030, down from ¥0.070 in the same quarter of 2020, reflecting a decrease of approximately 57.1%[21] Assets and Liabilities - Total assets increased by 5.90% to CNY 1,370,284,431.99 compared to the end of the previous year[5] - The company's total liabilities as of the third quarter of 2021 amounted to ¥471,269,524.81, an increase from ¥421,332,215.02 in the previous year, showing a rise of about 11.9%[18] - The total assets as of Q3 2021 were CNY 1,293,961,078.31, reflecting a decrease from CNY 1,432,862,354.87 at the beginning of the year[28] - The company’s total liabilities decreased to CNY 1,022,196,636.45 from CNY 1,161,097,913.01 at the start of the year[28] - Total liabilities amounted to ¥421,332,215.02, a decrease of ¥138,901,276.56 compared to the previous period[29] - Current liabilities totaled ¥246,260,471.39, while non-current liabilities were ¥175,071,743.63[29] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 30,493[11] - The largest shareholder, Dazhong Transportation Group, holds 16.37% of shares[11] - Shanghai Xinnanyang Angli Education Technology Co., Ltd. is the second-largest shareholder with a 13.53% stake[11] - The total equity attributable to shareholders reached ¥860,906,742.64, compared to ¥834,900,061.69 in the same period last year, marking an increase of approximately 3.1%[18] Cash Flow - Cash flow from operating activities increased by 67.59% to CNY 59,767,073.49 year-to-date[4] - Cash flow from operating activities for the first three quarters of 2021 was ¥266,397,229.75, compared to ¥246,752,497.20 in 2020, representing an increase of about 7.9%[23] - Net cash flow from operating activities for Q3 2021 was CNY 59,767,073.49, an increase of 67.5% compared to CNY 35,663,404.09 in Q3 2020[24] - Total cash inflow from investment activities was CNY 10,857,624.99, a decrease of 80.6% from CNY 55,913,541.19 in the previous year[24] - Cash flow from financing activities showed a net outflow of CNY 54,001,226.48, compared to a net outflow of CNY 129,196,439.61 in Q3 2020[25] Operational Costs and Expenses - Total operating costs for the first three quarters of 2021 were ¥239,402,966.95, compared to ¥221,565,183.14 in 2020, indicating an increase of about 8.0%[19] - Research and development expenses for the first three quarters of 2021 were ¥10,498,101.06, up from ¥8,316,124.31 in 2020, indicating a growth of about 26.3%[19] Strategic Relationships - The company has established a strategic relationship with its major shareholders, indicating potential for future collaboration and market expansion[13]